Sun Pharmaceutical Industries Shares Rally After Q2 Results

Large cap pharmaceuticals sector company Sun Pharmaceutical Industries shares today jumped 2.28% after the company reported stellar Q2 FY2025 results. The company declared its Q2 FY25 net profit at Rs 3040 crore, up 28%, beating estimates. The leading drugmaker announced its consolidated revenue from operations at Rs 13,291 crore for the quarter ended September 2024, up 9% YoY amid double digit growth across crucial markets, in particular the US market.

EBITDA of Sun Pharma for Q2 surged 23.9% to Rs 3,939 crore. Sun Pharma said it continues to invest heavily in research and development (R&D) to support its specialty pipeline.

Sun Pharmaceutical said its domestic sale surged 11% to Rs 4265 crore, accounting for 32% of total revenue. It introduced 14 new products this quarter and boosted its position as the market leader with a share increase to 8.1%. Revenue from the US jumped 20.3% to $517 million, enhanced by specialty sales, which jumped 19.2% to $286 million.

Sun Pharmaceutical Industries Shares Performance: The 52-week high price of Sun Pharmaceutical Industries shares on BSE is Rs 1960.20 per share (as on 30/09/2024) and 52-week low price is Rs 1069.00 per share (as on 31/10/2023), respectively. Sun Pharmaceutical Industries shares rose 51% so far in 2024, rose 92% in last 2-years, and surged 135% in last 3-years. Sun Pharmaceutical Industries shares offered phenomenal returns of 355% in last 5-years. The company has a market cap of Rs 4,56,498.32 crore.

About: Sun Pharma is the world's fourth largest specialty generics company with presence in Specialty, Generics and Consumer Healthcare products. It is the largest pharmaceutical company in India and is a leading generic company in the US as well as Global Emerging Markets. Sun's high growth Global Specialty portfolio spans innovative products in dermatology, ophthalmology, and onco-dermatology and accounts for over 16% of company sales. The company's vertically integrated operations deliver high-quality medicines, trusted by physicians and consumers in over 100 countries. Its manufacturing facilities are spread across six continents.